Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment

Prostate cancer (PC) remains a leading cause of morbidity and mortality among men worldwide, highlighting the need for novel therapeutic strategies. Our study investigates the therapeutic potential of targeting the heme degradation pathway through heme oxygenase-1 (HO-1) inhibition in PC. Using both...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramia J. Salloom, Dania Z. Sahtout, Iman M. Ahmad, Maher Y. Abdalla
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Translational Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325000701
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850074751820627968
author Ramia J. Salloom
Dania Z. Sahtout
Iman M. Ahmad
Maher Y. Abdalla
author_facet Ramia J. Salloom
Dania Z. Sahtout
Iman M. Ahmad
Maher Y. Abdalla
author_sort Ramia J. Salloom
collection DOAJ
description Prostate cancer (PC) remains a leading cause of morbidity and mortality among men worldwide, highlighting the need for novel therapeutic strategies. Our study investigates the therapeutic potential of targeting the heme degradation pathway through heme oxygenase-1 (HO-1) inhibition in PC. Using both in vitro and in vivo models, we explored the effects of combining HO-1 inhibition with chemotherapy, represented by docetaxel (Doc), on tumor growth and immune infiltration. In vitro experiments demonstrated that HO-1 inhibition, as well as HO-1 knockout (KO), significantly reduced tumor cell proliferation and enhanced chemosensitivity in RM-1 cells. Additionally, U937 cells co-cultured with HO-1 KO cells shifted cell polarization toward an M1 phenotype. In vivo, the combined treatment of the HO-1 inhibitor, tin protoporphyrin (SnPP), with Doc significantly enhanced anti-tumor efficacy in mouse models compared to chemotherapy or SnPP alone. This combination therapy not only reduced Ki67 expression and increased CC3 expression in tumor tissues but also shifted macrophage polarization toward an M1 phenotype and enhanced CD4+ and CD8+ T cells infiltration, indicating an augmented immune response. Further investigation using macrophage-specific HO-1 knockout mice revealed a direct role of HO-1 inhibition in driving macrophage polarization, confirming its involvement in promoting the shift toward an M1 phenotype. Although this response was significant, it was more robust with systemic HO-1 inhibition. Our findings indicate that HO-1 inhibition can potentiate the effects of chemotherapy, offering a promising avenue for improving PC treatment outcomes.
format Article
id doaj-art-7375eda86d9b449eb03c5bf30664301f
institution DOAJ
issn 1936-5233
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series Translational Oncology
spelling doaj-art-7375eda86d9b449eb03c5bf30664301f2025-08-20T02:46:29ZengElsevierTranslational Oncology1936-52332025-04-015410233910.1016/j.tranon.2025.102339Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatmentRamia J. Salloom0Dania Z. Sahtout1Iman M. Ahmad2Maher Y. Abdalla3Department of Pathology, Microbiology, and Immunology, USADepartment of Pathology, Microbiology, and Immunology, USADepartment of Clinical, Diagnostics, and Therapeutic Sciences, University of Nebraska Medical Center, Omaha, NE, USADepartment of Pathology, Microbiology, and Immunology, USA; Corresponding author.Prostate cancer (PC) remains a leading cause of morbidity and mortality among men worldwide, highlighting the need for novel therapeutic strategies. Our study investigates the therapeutic potential of targeting the heme degradation pathway through heme oxygenase-1 (HO-1) inhibition in PC. Using both in vitro and in vivo models, we explored the effects of combining HO-1 inhibition with chemotherapy, represented by docetaxel (Doc), on tumor growth and immune infiltration. In vitro experiments demonstrated that HO-1 inhibition, as well as HO-1 knockout (KO), significantly reduced tumor cell proliferation and enhanced chemosensitivity in RM-1 cells. Additionally, U937 cells co-cultured with HO-1 KO cells shifted cell polarization toward an M1 phenotype. In vivo, the combined treatment of the HO-1 inhibitor, tin protoporphyrin (SnPP), with Doc significantly enhanced anti-tumor efficacy in mouse models compared to chemotherapy or SnPP alone. This combination therapy not only reduced Ki67 expression and increased CC3 expression in tumor tissues but also shifted macrophage polarization toward an M1 phenotype and enhanced CD4+ and CD8+ T cells infiltration, indicating an augmented immune response. Further investigation using macrophage-specific HO-1 knockout mice revealed a direct role of HO-1 inhibition in driving macrophage polarization, confirming its involvement in promoting the shift toward an M1 phenotype. Although this response was significant, it was more robust with systemic HO-1 inhibition. Our findings indicate that HO-1 inhibition can potentiate the effects of chemotherapy, offering a promising avenue for improving PC treatment outcomes.http://www.sciencedirect.com/science/article/pii/S1936523325000701Heme oxygenase-1 (HO-1)Prostate cancer (PC)ZnPPSnPPand Docetaxel (Doc)
spellingShingle Ramia J. Salloom
Dania Z. Sahtout
Iman M. Ahmad
Maher Y. Abdalla
Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
Translational Oncology
Heme oxygenase-1 (HO-1)
Prostate cancer (PC)
ZnPP
SnPP
and Docetaxel (Doc)
title Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
title_full Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
title_fullStr Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
title_full_unstemmed Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
title_short Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment
title_sort synergistic effects of ho 1 inhibition and chemotherapy on tumor proliferation and immune infiltration an in vitro and in vivo approach to enhancing prostate cancer treatment
topic Heme oxygenase-1 (HO-1)
Prostate cancer (PC)
ZnPP
SnPP
and Docetaxel (Doc)
url http://www.sciencedirect.com/science/article/pii/S1936523325000701
work_keys_str_mv AT ramiajsalloom synergisticeffectsofho1inhibitionandchemotherapyontumorproliferationandimmuneinfiltrationaninvitroandinvivoapproachtoenhancingprostatecancertreatment
AT daniazsahtout synergisticeffectsofho1inhibitionandchemotherapyontumorproliferationandimmuneinfiltrationaninvitroandinvivoapproachtoenhancingprostatecancertreatment
AT imanmahmad synergisticeffectsofho1inhibitionandchemotherapyontumorproliferationandimmuneinfiltrationaninvitroandinvivoapproachtoenhancingprostatecancertreatment
AT maheryabdalla synergisticeffectsofho1inhibitionandchemotherapyontumorproliferationandimmuneinfiltrationaninvitroandinvivoapproachtoenhancingprostatecancertreatment